Treatment resistance is killing cancer patients.
It should not.

 

 
90%
of cancer patients die due to treatment resistance

Treatment monitoring is needed to detect resistance and adapt decisions.

Today's invasive sampling methods hinder regular monitoring.

Some cancer cells develop mechanisms to adapt and become resistant. As these cells become predominant patients stop responding to treatment.

 

Clinicians therefore need to know what form of resistance emerged to adapt therapy.

This is done by regular monitoring at molecular level:

1. Mutations in the genome

2. Changes in gene expression

Today, the only way to access this information is through sequencing tissue biopsy samples at single cell level.

 

Due to the invasiveness of tissue biopsy, 20% of cancer patients are not eligible. Another 20% run into complications. Therefore, tissue biopsy sampling is no option for treatment monitoring.

 

Parithera enables accurate treatment decision guidance & monitoring from one simple blood draw

An alternative to tissue biopsy is to study cells which detach from the solid tumors and find access to the blood stream. The so-called circulating tumor cells (CTCs) are retrieved via Liquid Biopsy.

 

Parithera ExTrace enables clinicians to monitor treatment response and choose the best therapy based on single cell RNA (scRNA) sequencing data.

Parithera’s innovative approach is based on two inventions in the domain of CTC isolation and sequencing preparation. -> More on the technology